RxDoctor Payments Data

Prabha Ranganathan, MD

Rheumatology · Saint Louis, MONPI 1003832304

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (43.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 70.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $2,894 and has fallen 53.0% since, to $1,359 in 2025.

$6,200in general payments, 2019–2025

Across 32 payments — averaging $193.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • Astrazeneca UK Limited$1K
  • Pfizer$134
  • AstraZeneca$107
  • GSK$100
  • Johnson & Johnson$99
  • plus $184 from 3 others

What the payments were for

  • Consulting fees$1,50024%
  • Speaking & faculty fees$2,70044%
  • Travel & lodging$92515%
  • Food & beverage$88014%
  • Education$1953%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)6$4,363
Astrazeneca UK Limited6$1,213
Pfizer7$134
AstraZeneca1$107
GSK1$100
Johnson & Johnson1$99
AbbVie5$95
E.r. Squibb & Sons, L.L.C.4$59
UCB, Inc.1$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,200 in reported general payments places this provider in the 70th percentile of 134 rheumatology providers in Missouri.

See all rheumatology providers in Missouri

Medicare billing

Part B allowed, 2024
$64,232
Medicare patients
246
Services billed
1,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab68$741,086
Humira(Cf)Adalimumab28$400,526
Enbrel SureclickEtanercept34$329,865
OrenciaAbatacept26$148,338
HumiraAdalimumab13$104,753
Humira PenAdalimumab14$86,643
MethotrexateMethotrexate Sodium221$5,247
Leflunomide70$4,691
Hydroxychloroquine Sulfate107$3,749
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen33$1,166
Azathioprine17$918
Sulfasalazine30$730
Prednisone84$678
Diclofenac Sodium11$564
Folic Acid29$291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf), Humira$95$505,27941 claims
E.r. Squibb & Sons, L.L.C.Orencia$59$148,33826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 134 rheumatology providers in Missouri.

Other rheumatology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →